Bioventus (NASDAQ:BVS) Upgraded to “Strong-Buy” at Barrington Research

Barrington Research upgraded shares of Bioventus (NASDAQ:BVS) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.

Separately, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy”.

Bioventus Price Performance

BVS stock traded up $0.13 during trading on Monday, hitting $8.65. The stock had a trading volume of 34,193 shares, compared to its average volume of 237,271. Bioventus has a twelve month low of $5.81 and a twelve month high of $11.25. The company’s 50-day moving average price is $7.72 and its two-hundred day moving average price is $7.28. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.74 and a quick ratio of 1.14. The stock has a market capitalization of $715.87 million, a P/E ratio of 72.09 and a beta of 0.80.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.